智通财经网·2025-07-28 10:23Core Insights - WuXi AppTec (02359) reported an unaudited interim performance for the six months ending June 30, 2025, with revenue of 20.799 billion RMB, a year-on-year increase of 20.6% [1] - The gross profit reached 9.112 billion RMB, up 36% year-on-year, while the net profit attributable to shareholders was 8.287 billion RMB, reflecting a significant increase of 95.5% [1] - The company proposed an interim dividend of 3.5 RMB per 10 shares [1] Revenue Breakdown - The company’s revenue from ongoing operations was 20.41 billion RMB, with significant contributions from various regions: 14.03 billion RMB from U.S. clients (up 38.4%), 2.33 billion RMB from European clients (up 9.2%), 3.15 billion RMB from Chinese clients (down 5.2%), and 0.9 billion RMB from other regions (up 7.6%) [1] Chemical Business Performance - The chemical business generated revenue of 16.3 billion RMB, marking a year-on-year growth of 33.5% [2] - The small molecule drug discovery segment successfully synthesized and delivered over 440,000 new compounds in the past twelve months [2] - The small molecule development and manufacturing (D&M) segment reported revenue of 8.68 billion RMB, a 17.5% increase year-on-year, with a total of 3,409 molecules in the pipeline as of June 30, 2025 [2] TIDES Business Growth - The TIDES business (oligonucleotides and peptides) experienced rapid growth, with revenue reaching 5.03 billion RMB, a remarkable increase of 141.6% [3] - The backlog of TIDES orders grew by 48.8% year-on-year, with a 12% increase in the number of clients served and a 16% increase in the number of molecules served [3] - The company is expanding its peptide production capacity, expecting the total volume of solid-phase synthesis reactors to exceed 100,000L by the end of 2025 [3]